Literature DB >> 26984592

Multiple myeloma with Russell bodies and needle-shaped crystalline inclusions.

Toshiki Yamada1, Yasuhito Nannya2,3, Naoki Mita4, Masahito Shimizu2, Mitsuru Seishima3,5, Hisashi Tsurumi6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26984592     DOI： 10.1007/s12185-016-1985-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Auer rod-like inclusions in a low-grade B-cell leukemia.

Authors:  Alexandra C Hristov; Andrew Saladino; Victor E Nava; Christopher D Gocke
Journal:  Ann Diagn Pathol       Date:  2010-04-02       Impact factor: 2.090

2.  [Plasma-cells crystal-like inclusions two cases of monoclonal gammapathy (author's transl)].

Authors:  P Henon; J P Leclerc; C Marsan; I Gerota; D M Ortin; J C Sauvegrain
Journal:  Arch Anat Cytol Pathol       Date:  1976

3.  Numerous Russell bodies and Dutcher bodies in multiple myeloma.

Authors:  Adriaan J van Gammeren; Luthy S M Alcala; Magda Smolders; Rinske S Boersma
Journal:  Br J Haematol       Date:  2014-10-14       Impact factor: 6.998

4.  Light chain crystal deposition as a manifestation of plasma cell dyscrasias: the role of immunoelectron microscopy.

Authors:  Xin Gu; Roberto Barrios; Joiner Cartwright; Ramon L Font; Luan Truong; Guillermo A Herrera
Journal:  Hum Pathol       Date:  2003-03       Impact factor: 3.466

5.  Needle-shaped inclusions in plasma cells in a patient with hypogammaglobulinemia.

Authors:  H Nakamine; T Nishihara; K Saito; T Takenaka; J Maeda
Journal:  Am J Clin Pathol       Date:  1982-10       Impact factor: 2.493

6.  Multiple myeloma with crystalline inclusions in most hemopoietic cells.

Authors:  L Gabriel; L Escribano; J Perales; C Bellas; J Odriozola; J L Navarro
Journal:  Am J Hematol       Date:  1985-04       Impact factor: 10.047

Review 7.  Intracellular and extracellular rhomboid shaped crystalline inclusions in a case of IgG lambda restricted plasma cell myeloma: a case report and review of the literature.

Authors:  Andres Matoso; Tina Rizack; Diana O Treaba
Journal:  Diagn Pathol       Date:  2010-01-21       Impact factor: 2.644

8.  Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.

Authors:  Hironori Harada; Mitsumasa Watanabe; Kenshi Suzuki; Soshi Yanagita; Takahiro Suzuki; Yataro Yoshida; Akiro Kimura; Mitsuru Tsudo; Akira Matsuda; Kaoru Tohyama; Masafumi Taniwaki; Kenichi Takeshita; Masaaki Takatoku; Keiya Ozawa
Journal:  Int J Hematol       Date:  2009-08-25       Impact factor: 2.490

9.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.